Geert D'Haens | SEBRADII 2021 | Galoá Proceedings

Geert D'Haens

Is this your profile? Do login to access your certificates

Non-invasive predictors of maintaining remission in patients with moderately to severely active UC treated with tofacitinib who dose reduced from tofacitinib 10mg BID to 5mg BID: 6-month data from the double-blind, randomized RIVETING study
Geert D'Haens ¹
Marla Dubinski ²
Miguel Regueiro ³
Genoile Santana ⁴
Joana Torres ⁵
Nicole Kulisek ⁶
Sean Gardiner ⁶
Rajiv Mundayat ⁶
Jerome Paulissen ⁶
Nervin Lawendy ⁶
Chinyu Su ⁶
Irene Modesto ⁶
William Sandborn ⁷
¹ Amsterdam University Medical Centres, Amsterdam, The Netherlands
² Icahn School of Medicine at Mount Sinai
³ Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, Ohio, United States
⁴ Universidade do Estado da Bahia
⁵ Hospital Beatriz Ângelo, Loures, Portugal
⁶ Pfizer Inc.
⁷ University of California
Vol 2, 2021 -
139328

1. Medicina

Trabalho Original
Impact of prior TNFi failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with UC who were in stable remission: 6-month data from the double-blind, randomised RIVETING study
William Sandborn ¹
Marla Dubinski ²
Joana Torres ³
Severine Vermeire ⁴
Paulo Gustavo Kotze ⁵
Chinyu Su ⁶
Nervin Lawendy ⁶
Jerome Paulissen ⁶
Rajiv Mundayat ⁶
Sean Gardiner ⁶
Nicole Kulisek ⁶
Irene Modesto ⁶
Geert D'Haens ⁷
¹ University of California
² Icahn School of Medicine at Mount Sinai
³ Hospital Beatriz Ângelo, Loures, Portugal
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ Pontifícia Universidade Católica do Paraná
⁶ Pfizer Inc.
⁷ Amsterdam University Medical Centres, Amsterdam, The Netherlands
Vol 2, 2021 -
139316

1. Medicina

Trabalho Original

Co-authors (14)